Differentiation syndrome in acute promyelocytic leukaemia
Top Cited Papers
- 1 October 2019
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 187 (2), 157-162
- https://doi.org/10.1111/bjh.16151
Abstract
Acute promyelocytic leukaemia differentiation syndrome (APL DS) is seen when patients with APL are treated with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). Presenting symptoms are varied but frequently include dyspnoea, unexplained fever, weight gain >5 kg, unexplained hypotension, acute renal failure and a chest radiograph demonstrating pulmonary infiltrates or pleural or pericardial effusion. Immediate treatment with steroids at the first clinical suspicion is recommended and ATRA/ATO should be stopped in severe cases or if there is no response to treatment. The utility of steroid prophylaxis in order to prevent APL DS is less certain. Here we provide a detailed review of the pathogenesis, clinical signs and symptoms as well as management and prophylaxis strategies of APL DS.Keywords
This publication has 17 references indexed in Scilit:
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaThe New England Journal of Medicine, 2013
- All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Blood, 2012
- Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupBlood, 2010
- Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeBlood, 2010
- Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab OzogamicinJournal of Clinical Oncology, 2009
- Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factorsBlood, 2009
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA GroupBlood, 2008
- Diffuse Alveolar Hemorrhage with Underlying Pulmonary Capillaritis in the Retinoic Acid SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 1998
- All‐trans‐RETINOIC ACID INCREASES ADHESION TO ENDOTHELIUM OF THE HUMAN PROMYELOCYTIC LEUKAEMIA CELL LINE NB4British Journal of Haematology, 1996
- The "Retinoic Acid Syndrome" in Acute Promyelocytic LeukemiaAnnals of Internal Medicine, 1992